Table 4 Plasma lipids significantly (p < 0.05) associated with baseline eGFR. Effect size represents the magnitude and direction (+/−) of association between a given lipid and eGFR, estimated by linear regression, while controlling for the selected HALT covariates, age, sex, genotype, site of sample collection, and BMI
Lipid | Effect Size (SD) | p-value | FDR q-value |
|---|---|---|---|
Acylcarnitine(10:1) [M + H]+ | −0.0424 (0.013) | 0.0010 | 0.0737 |
Triglyceride(53:3) [M + K]+ | −0.0516 (0.017) | 0.0033 | 0.1024 |
Acylcarnitine(14:2) [M + H]+ | −0.0303 (0.011) | 0.0057 | 0.1024 |
Acylcarnitine(12:1) [M + H]+ | −0.0350 (0.013) | 0.0059 | 0.1024 |
Acylcarnitine(8:0) [M + H]+ | −0.0291 (0.011) | 0.0071 | 0.1024 |
Triglyceride(54:5) A [M + K]+ | −0.0470 (0.020) | 0.0199 | 0.2364 |
Phosphatidylcholine(28:0) [M + H]+ | 0.0275 (0.012) | 0.0229 | 0.2364 |
Phosphatidylcholine(38:7) [M + H]+ | 0.0578 (0.028) | 0.0397 | 0.2959 |
Triglyceride(59:3) [M + NH4]+ | −0.0320 (0.015) | 0.0399 | 0.2959 |
Diglyceride(32:0) [M + K]+ | 0.0506 (0.025) | 0.0409 | 0.2959 |
Phosphatidylcholine(30:0) [M + H]+ | 0.0307 (0.015) | 0.0477 | 0.3137 |